Current hormonal therapies for breast cancer, also known as antiestrogen therapies, usually target various types of ERs and selective ER modulators (SERMs) (27, 28) by default, for the treatment and prevention of breast cancers (29, 30), demonstrating the limitation of current endocrine therapy. This evidence concerns the gene ESR1 and breast cancer.